Phase I trial of spirogermanium given by infusion in a multiple-dose schedule.
In a phase I study of spirogermanium, a new azaspiran-germanium compound, 28 patients were given a multiple-dose schedule. When infused over 1 hour, the maximum tolerated single dose of this agent was greater than 120 mg/m2 but significant chronic neurologic toxicity occurred after 1-2 weeks of treatment. Patients with a poor performance status (PS) were the most likely to manifest toxic reactions. Suggested phage II dose levels for infusion treatment with spirogermanium are 120 mg/m2 for patients with a PS of 0-2 and 80 mg/m2 for patients with a PS of 3.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005857:Germanium / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D013141:Spiro Compounds / Q000008:administration & dosage* / Q000009:adverse effects
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D013141:Spiro Compounds; D005857:Germanium; C026818:spirogermanium